Anatara Lifesciences Ltd
ANR
Company Profile
Business description
Anatara Lifesciences Ltd develops and commercializes evidence-based products addressing unmet needs in gastrointestinal health. The company focuses on building a pipeline of human health products, particularly targeting complex gastrointestinal conditions. It operates through a single reportable segment encompassing the research and development of oral solutions for gastrointestinal diseases and the commercialization of Detach, a diarrhea treatment for piglets.
Contact
c/- Perks, 81 Flinders Street
Level 8
AdelaideSA5000
AUST: +61 438027172
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
Stocks News & Analysis
stocks
AI lands a blow on some Aussie stocks – yet stands to benefit others
AI is reshaping ASX tech moats - but some are more insulated than others.
stocks
This might be the best core stock bargain in the US market today
Patient investors should consider building a position in this wide-moat stock while it’s seriously undervalued.
stocks
Data center demand drives strong earnings outlook for SGM
Sims guides huge earnings upgrade as data center metals demand spikes.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,556.10 | 80.50 | 0.95% |
| CAC 40 | 7,665.62 | 142.25 | -1.82% |
| DAX 40 | 22,380.19 | 459.37 | -2.01% |
| Dow JONES (US) | 45,577.47 | 443.96 | -0.96% |
| FTSE 100 | 9,918.33 | 145.17 | -1.44% |
| HKSE | 24,439.40 | 837.92 | -3.31% |
| NASDAQ | 21,647.61 | 443.08 | -2.01% |
| Nikkei 225 | 51,594.48 | 1,778.05 | -3.33% |
| NZX 50 Index | 12,899.72 | 90.27 | -0.69% |
| S&P 500 | 6,506.48 | 100.01 | -1.51% |
| S&P/ASX 200 | 8,370.20 | 86.70 | 1.05% |
| SSE Composite Index | 3,855.31 | 101.74 | -2.57% |